Indoximod

DRACPC ID  DRACPC0091

Active Ingredients   Indoximod

Description  A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.

Synonyms  1-Methyl-D-tryptophan; 1-MT; D-(+)-1-Methyltryptophan; D-1MT; Indoximod

Type  Small Molecule

Disease  Glioma, Melanoma, Ependymoma, Gliosarcoma, Lung Cancer

Classification

  

Enzyme IDO inhibitor Amino acid and derivative Immunosuppressant

Structure Information


Molecular Formula  C12H14N2O2

Molecular Weight  218.3

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid

InChI  InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1

InChI_Key ZADWXFSZEAPBJS-SNVBAGLBSA-N

SMILES  O=C(O)[C@H](N)CC1=CN(C)C2=C1C=CC=C2

External Codes


PubChem CID  405012

DrugBank Accession Number  DB12827

NCI Thesaurus Code  C71535  

UNII  TX5CYN1KMZ   GSRS

CAS  110117-83-4



Drug approval


Drug indication
    Indoximod has been used in trials studying the treatment of Glioma, Melanoma, Ependymoma, Gliosarcoma, and Lung Cancer, among others.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01560923 A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer Metastatic Prostate Cancer Phase 2 Treatment
NCT02835729 A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia Phase 1 Treatment
NCT03301636 A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma Melanoma Phase 2/3 Treatment
NCT05106296 Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer Ependymoma; Medulloblastoma; Glioblastoma; Primary Brain Tumor Phase 1 Treatment
NCT01042535 A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific Phase 1/2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.